<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073811435916</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073811435916</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of Melatonin on Seizure Frequency in Intractable Epilepsy</article-title>
<subtitle>A Pilot Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Goldberg-Stern</surname>
<given-names>Hadassa</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073811435916">1</xref>
<xref ref-type="aff" rid="aff2-0883073811435916">2</xref>
<xref ref-type="corresp" rid="corresp1-0883073811435916"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oren</surname>
<given-names>Heftsiba</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073811435916">2</xref>
<xref ref-type="aff" rid="aff3-0883073811435916">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peled</surname>
<given-names>Nir</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-0883073811435916">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garty</surname>
<given-names>Ben-Zion</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073811435916">2</xref>
<xref ref-type="aff" rid="aff5-0883073811435916">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0883073811435916">
<label>1</label>Department of Child Neurology, Epilepsy Center, Schneider Children’s Medical Center of Israel, Petah Tiqwa, Israel</aff>
<aff id="aff2-0883073811435916">
<label>2</label>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</aff>
<aff id="aff3-0883073811435916">
<label>3</label>Medical Corps, Israel Defense Forces, Israel</aff>
<aff id="aff4-0883073811435916">
<label>4</label>Department of Pulmonary Medicine, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel</aff>
<aff id="aff5-0883073811435916">
<label>5</label>Kipper Institute of Pediatric Immunology and the Department of Pediatrics B, Schneider Children’s Medical Center of Israel, Petah Tiqwa, Israel</aff>
<author-notes>
<corresp id="corresp1-0883073811435916">Hadassa Goldberg-Stern, MD, Epilepsy Center, Schneider Children’s Medical Center of Israel, 14 Kaplan Street, Petah Tiqwa 49202, Israel Email: <email>hagoldberg@clalit.org.il</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>12</issue>
<fpage>1524</fpage>
<lpage>1528</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>12</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Melatonin is effective for treating sleep–wake cycle disturbances and has been reported occasionally to decrease epileptic seizure frequency, with no long-term side effects. In this pilot study, the investigators examined the effect of melatonin on seizures, sleep quality, and behavior in 10 patients aged 9 to 32 years with intractable epilepsy. Patients were randomized to receive melatonin (10 mg daily at bedtime) followed by placebo or placebo followed by melatonin for 3 weeks each, with a 1-week washout period in between. Seizure frequency was monitored by daily diaries and actigraphy recordings; behavioral and sleep parameters were rated by caregivers. Diurnal seizures decreased significantly with melatonin compared with placebo (<italic>P = </italic>.034, Wilcoxon test). Maximal number of seizures, seizure duration, sleep efficiency or latency, and behavioral parameters remained unchanged. No major side effects or seizure aggravation were documented. It is concluded that melatonin could be effective and safe for decreasing daytime seizure frequency in patients with intractable epilepsy.</p>
</abstract>
<kwd-group>
<kwd>melatonin</kwd>
<kwd>epilepsy</kwd>
<kwd>sleep</kwd>
<kwd>antiepileptic effect</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>It is well known that sleep deprivation can provoke seizures. The question to be asked, therefore, is whether improvement in sleep leads to better seizure control. Melatonin is an indoleamine hormone synthesized by the pineal gland and released in a circadian pattern, with a peak at night.<sup><xref ref-type="bibr" rid="bibr1-0883073811435916">1</xref></sup> It is used in the pediatric population to treat sleep disturbances in patients with learning disabilities and visual or behavioral disorders.<sup><xref ref-type="bibr" rid="bibr2-0883073811435916">2</xref>
<xref ref-type="bibr" rid="bibr3-0883073811435916"/>
<xref ref-type="bibr" rid="bibr4-0883073811435916"/>
<xref ref-type="bibr" rid="bibr5-0883073811435916"/>
<xref ref-type="bibr" rid="bibr6-0883073811435916"/>
<xref ref-type="bibr" rid="bibr7-0883073811435916"/>
<xref ref-type="bibr" rid="bibr8-0883073811435916"/>–<xref ref-type="bibr" rid="bibr9-0883073811435916">9</xref></sup>
</p>
<p>The first clinical application of melatonin for seizures was prompted by the finding of Anton-Tay<sup><xref ref-type="bibr" rid="bibr10-0883073811435916">10</xref></sup> in 1974 that melatonin lowers the electrical amplitude on electroencephalographic (EEG) recordings. In a preliminary study, Anton-Tay and his group treated 6 epilepsy patients with 2 mg of melatonin daily for 30 days and documented a reduction in seizure frequency and no improvement in EEG.<sup><xref ref-type="bibr" rid="bibr10-0883073811435916">10</xref></sup>
</p>
<p>Given that cortical excitability may be involved in reducing the central motor seizure inhibition caused by sleep deprivation, Scalise et al<sup><xref ref-type="bibr" rid="bibr11-0883073811435916">11</xref></sup> suggested that the improvement in sleep quality induced by melatonin contributes to its effect in reducing seizure frequency. Others attributed melatonin’s antiepileptic activity to its potent free-radical scavenging properties.<sup><xref ref-type="bibr" rid="bibr1-0883073811435916">1</xref></sup> Support for this assumption was provided by studies showing that intraventricular injection of antimelatonin antibodies led to epileptic activity<sup><xref ref-type="bibr" rid="bibr12-0883073811435916">12</xref></sup> and that the administration of the benzodiazepine antagonist R015-1788 blunted the anticonvulsant response to melatonin.<sup><xref ref-type="bibr" rid="bibr13-0883073811435916">13</xref></sup> Niles et al<sup><xref ref-type="bibr" rid="bibr14-0883073811435916">14</xref></sup> proposed that melatonin could increase the concentration of γ-aminobutyric acid (GABA). Castroviejo et al<sup><xref ref-type="bibr" rid="bibr15-0883073811435916">15</xref></sup> demonstrated in 1986 that the affinity of the benzodiazepine–GABA receptor complex increased after melatonin administration. Alternatively, melatonin might inhibit the influx of calcium into neurons and its subsequent binding to calmodulin, which would ultimately reduce nitric oxide production and the excitatory effect of <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA).<sup><xref ref-type="bibr" rid="bibr16-0883073811435916">16</xref></sup> The findings in rat models of enhancement effect of carbamazepine and phenobarbital by melatonin may be extrapolated to humans.<sup><xref ref-type="bibr" rid="bibr17-0883073811435916">17</xref></sup>
</p>
<p>So far, none of the data on the effect of melatonin on behavior in children<sup><xref ref-type="bibr" rid="bibr18-0883073811435916">18</xref>
<xref ref-type="bibr" rid="bibr19-0883073811435916"/>–<xref ref-type="bibr" rid="bibr20-0883073811435916">20</xref></sup> and none of the few studies reporting a benefit of melatonin in seizures have been based on double-blind trials. The aim of the present pilot study was to evaluate the effect of melatonin on seizure frequency in patients with intractable epilepsy using a double-blind, crossover, placebo-controlled design.</p>
<sec id="section1-0883073811435916" sec-type="methods">
<title>Methods</title>
<sec id="section2-0883073811435916">
<title>Patients and Setting</title>
<p>Patients were recruited from the Epilepsy Clinic of Schneider Children’s Medical Center of Israel. Inclusion criteria were age 4 years or more, failure of at least 3 different antiepileptic drugs to control seizures, therapeutic stability for 2 months prior to the study, and 4 seizures or more in the 3 weeks prior to the initiation of the study (based on inclusion criteria for international drug studies for epilepsy). Patients with vasculitis syndromes, cardiovascular anomalies, or blindness were excluded. The sample size was determined after offering all families of children with intractable epilepsy who met the inclusion criteria (30 families) to participate in the study during a 3-month enrollment period. Of these, 12 agreed to participate.</p>
<p>The study protocol was approved by the Helsinki Committee of Rabin Medical Center, Petach Tikva, Israel. All participating patients or their legal guardians (for those younger than 18 years) signed an informed consent form.</p>
<p>Patients were randomly assigned to receive treatment with melatonin or placebo for 3 weeks (stage 1). After a 1-week washout period, patients who started with melatonin were switched to placebo and vice versa for an additional 3 weeks (stage 2). Thus, each patient served as his or her own control. Randomization was undertaken by the pharmacist and was unknown to the physicians who participated in the study or to the patients. Fifty percent of the sample comprised young adults; all had childhood onset epilepsy and therefore continued to be cared for and followed at the Epilepsy Center at Schneider Children’s Medical Center of Israel.</p>
<p>Melatonin was administered in the form of fast-release, 10-mg tablets. The placebo pills were identical in size and appearance to the melatonin pills and were prepared by the same pharmacist. Patients were instructed to take 1 tablet daily, 1 hour before bedtime, in addition to their regular antiepileptic regimen.</p>
</sec>
<sec id="section3-0883073811435916">
<title>Assessment</title>
<p>During each stage of the crossover study and the washout period, the patients’ caregivers were asked to complete 3 daily diaries, in tabular form, as follows:
<list list-type="order">
<list-item>
<p>Seizures table, documenting the occurrence, type (partial vs generalized, according to International League Against Epilepsy classification),<sup><xref ref-type="bibr" rid="bibr21-0883073811435916">21</xref>,<xref ref-type="bibr" rid="bibr22-0883073811435916">22</xref></sup> timing, and duration of every seizure that occurred</p>
</list-item>
<list-item>
<p>Sleep table, documenting the daily time of administration of melatonin, estimated interval from drug intake to falling asleep, estimated or known wake-up time, number and duration of arousals during the night, and nap time the next day</p>
</list-item>
<list-item>
<p>Behavior table, rating behavioral parameters on a 7-point scale, from 0 (very low) to 7 (very high), as follows: daytime sleepiness, difficulty in falling asleep and waking up, agitation and concentration levels.</p>
</list-item>
</list></p>
<p>Caregivers were also asked to note patient compliance with the study treatment and any possible side effects.</p>
<p>Actigraphy devices were used to record total sleep time and sleep structures in addition to patient activity (in 9 patients) during the second week of each stage.</p>
</sec>
</sec>
<sec id="section4-0883073811435916">
<title>Statistical Analysis</title>
<p>Data were analyzed by Wilcoxon test using the SPSS. <italic>P</italic> &lt; .05 was considered statistically significant.</p>
<p>Partial or generalized seizures were recorded on the basis of the International League Against Epilepsy classification (partial seizures include simple/complex, generalized seizures include absences, myoclonic, generalized tonic–clonic seizures, atonic, and tonic). In the statistical analysis, partial versus generalized were compared.</p>
</sec>
<sec id="section5-0883073811435916">
<title>Results</title>
<p>The study group included 12 patients (7 female, 5 male) aged 9 to 32 years. Two patients were dropped from the analysis because of lack of compliance in completing the diaries. The clinical data of the patients are summarized in <xref ref-type="table" rid="table1-0883073811435916">Table 1</xref>.</p>
<table-wrap id="table1-0883073811435916" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical Features of 10 Children With Intractable Epilepsy</p>
</caption>
<graphic alternate-form-of="table1-0883073811435916" xlink:href="10.1177_0883073811435916-table1.tif"/>
<table>
<thead>
<tr>
<th>Patient Number</th>
<th>Age at Start of Study, y</th>
<th>Age at Seizure Onset</th>
<th>Epilepsy Duration, y</th>
<th>Origin of Seizure </th>
<th>Epilepsy Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15</td>
<td>2 d</td>
<td>15</td>
<td>Hypoxic ischemic encephalopathy, perinatal hypoglycemia</td>
<td>Symptomatic, generalized</td>
</tr>
<tr>
<td>2</td>
<td>17</td>
<td>2 mo</td>
<td>17</td>
<td>Excision of right frontal lobe ganglion cell tumor</td>
<td>Symptomatic, partial with secondary generalization</td>
</tr>
<tr>
<td>3</td>
<td>32</td>
<td>8 mo</td>
<td>31</td>
<td>Left side porencephalic cyst, partial corpus callosotomy and shunt placement</td>
<td>Symptomatic, partial</td>
</tr>
<tr>
<td>4</td>
<td>14.5</td>
<td>8 y</td>
<td>6.5</td>
<td>Unknown</td>
<td>Cryptogenic, partial with secondary generalization</td>
</tr>
<tr>
<td>5</td>
<td>23</td>
<td>3 y</td>
<td>20</td>
<td>Unknown</td>
<td>Cryptogenic, partial with secondary generalization</td>
</tr>
<tr>
<td>6</td>
<td>24</td>
<td>15 mo</td>
<td>22</td>
<td>Left mesiotemporal sclerosis</td>
<td>Idiopathic, partial</td>
</tr>
<tr>
<td>7</td>
<td>17</td>
<td>5 mo</td>
<td>17</td>
<td>Unknown</td>
<td>Cryptogenic, partial with secondary generalization</td>
</tr>
<tr>
<td>8</td>
<td>23</td>
<td>5 y</td>
<td>18</td>
<td>Suspected mitochondrial disease</td>
<td>Symptomatic, generalized (myoclonic, tonic–clonic)</td>
</tr>
<tr>
<td>9</td>
<td>13</td>
<td>6.5 y</td>
<td>6.5</td>
<td>Intrathecal chemotherapy for acute lymphoblastic leukemia</td>
<td>Symptomatic, generalized</td>
</tr>
<tr>
<td>10</td>
<td>26</td>
<td>6 y</td>
<td>20</td>
<td>Familial frontotemporal pachygyria</td>
<td>Symptomatic, generalized (drop attacks)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The caregivers reported good compliance to treatment and no side effects at any point in the study.</p>
<sec id="section6-0883073811435916">
<title>Seizure Parameters</title>
<p>The mean number of diurnal seizures in the study group during placebo treatment was 7.75 and during melatonin treatment 4.6. This difference was statistically significant (<italic>P</italic> = .034, Wilcoxon test). Three patients showed a decrease of 50% or more in diurnal seizures during melatonin treatment relative to placebo (responder rate 30%).</p>
<p>Separate analysis of partial and generalized seizures yielded a decrease in mean frequency of partial seizures from 8.31 under placebo treatment to 5.26 under melatonin treatment (<italic>P</italic> = .208, Wilcoxon test). There were no statistically significant changes in the frequency of generalized or nocturnal seizures, maximal number of seizures per day, or duration of seizures.</p>
<p>Three patients chose to continue taking melatonin treatment after the study period.</p>
</sec>
<sec id="section7-0883073811435916">
<title>Sleep Parameters</title>
<p>Analyses of the sleep diaries and actigraphy records yielded no statistically significant improvement in sleep efficiency or shorter sleep latency during treatment with melatonin compared with placebo.</p>
</sec>
<sec id="section8-0883073811435916">
<title>Behavior Parameters</title>
<p>No statistically significant changes were found in any of the behavioral parameters during melatonin treatment compared with placebo.</p>
</sec>
</sec>
<sec id="section9-0883073811435916">
<title>Discussion</title>
<p>In the present prospective pilot study using a double-blind, placebo-controlled, crossover design, treatment with melatonin was found to be associated with a statistically significant decrease in diurnal seizure frequency compared with placebo in patients with intractable epilepsy, with no adverse effects and no documented seizure aggravation.</p>
<fig id="fig1-0883073811435916" position="float">
<label>Figure 1.</label>
<caption>
<p>Flow chart of study stages (crossover design).</p>
</caption>
<graphic xlink:href="10.1177_0883073811435916-fig1.tif"/>
</fig>
<p>The current data on the benefit of melatonin in alleviating seizures in children with epilepsy are conflicting. Peled et al<sup><xref ref-type="bibr" rid="bibr4-0883073811435916">4</xref></sup> reported a significant clinical improvement in seizure control at night in 5 of 6 children treated with 3 mg of melatonin 30 minutes before bedtime. Ross et al<sup><xref ref-type="bibr" rid="bibr23-0883073811435916">23</xref></sup> evaluated 24 epileptic patients aged 1 to 13 years with some type of sleep disorder who were treated with a fast-release preparation of melatonin; doses ranged from 2.5 to 7.5 mg for those aged less than 2 years and from 2.5 to 10 mg (like our study dose) for older children. Twenty had a good response in terms of seizure control, and most showed improved sleep. Molina-Carballo et al<sup><xref ref-type="bibr" rid="bibr24-0883073811435916">24</xref></sup> described a 1-year-old girl with intractable myoclonic epilepsy given adjuvant therapy with high-dose melatonin (100 mg twice daily) for 2 years. The number of seizures dropped from 20 per day to 0. On discontinuation of melatonin, the seizures reappeared.</p>
<p>Our observation that melatonin may help to decrease seizure frequency is also supported by recent findings of lower levels of melatonin in children with refractory epilepsy<sup><xref ref-type="bibr" rid="bibr25-0883073811435916">25</xref></sup> and an increase in melatonin levels after seizures.<sup><xref ref-type="bibr" rid="bibr26-0883073811435916">26</xref></sup>
</p>
<p>By contrast, however, others found that melatonin may increase human epileptic activity.<sup><xref ref-type="bibr" rid="bibr27-0883073811435916">27</xref>,<xref ref-type="bibr" rid="bibr28-0883073811435916">28</xref></sup> Coppola et al<sup><xref ref-type="bibr" rid="bibr29-0883073811435916">29</xref></sup> conducted a double-blind, crossover, placebo-controlled trial in 25 patients aged 3.5 to 26 years with wake–sleep disorders and mental retardation. Eighteen older patients had epilepsy and were on a chronic stable antiepileptic regimen. Treatment with 2 mg of melatonin was well tolerated, with no side effects, and half the caregivers reported an improvement in behavior and alertness. However, seizure control was disappointing: in 2 of the 11 seizure-free patients, seizures reappeared after melatonin was started and stopped soon after its discontinuation. Of the 7 patients with uncontrolled epilepsy at baseline, 1 became seizure-free, 2 partially improved, 2 remained unchanged, and 2 worsened.</p>
<p>Our study had an advantage over previous studies because the crossover design made it possible to evaluate the positive and negative effects of melatonin in the same patients. However, it was limited by a small sample size and by a short period of follow-up, which may increase the possibility of chance findings. Furthermore, we were unable to perform 2 polysomnography studies for each patient, so we could not determine whether the mechanism underlying the decrease in diurnal (but not nocturnal) seizure frequency under melatonin treatment involves the positive influence of melatonin on sleep parameters.</p>
<p>Another limitation of our study was that melatonin was administered without measuring the dim light melatonin onset, which is an important tool for analysis of circadian phase in human sleep.<sup><xref ref-type="bibr" rid="bibr27-0883073811435916">27</xref></sup> Van Geijlswijk et al<sup><xref ref-type="bibr" rid="bibr30-0883073811435916">30</xref></sup> demonstrated in 2010 that melatonin is effective for chronic idiopathic sleep insomnia in a dosage of 0.05 mg/kg given at least 1 to 2 hours before dim light melatonin onset and before desired bedtime.</p>
<p>We chose to use a relatively high dose of melatonin in our study based on our previous experience<sup><xref ref-type="bibr" rid="bibr4-0883073811435916">4</xref></sup> and that of others.<sup><xref ref-type="bibr" rid="bibr23-0883073811435916">23</xref></sup> However, it has been reported that slow metabolizers of melatonin may require a lower dose of the medication.<sup><xref ref-type="bibr" rid="bibr31-0883073811435916">31</xref></sup> Another drawback in our study design relates to the fact that stopping melatonin treatment probably does not immediately reverse circadian rhythms to the pretreatment level. Consequently, melatonin may still have an effect even though we used a 1 week washout period.</p>
<p>In conclusion, our double-blind, placebo-controlled crossover pilot study demonstrated that melatonin may be effective and safe in decreasing daytime seizure frequency in young people with intractable epilepsy with no seizure aggravation effect. This finding has important implications for the use of melatonin as an add-on treatment in this setting. Further prospective double-blind studies are needed in larger cohorts to determine whether melatonin has an independent or nonspecific (via its beneficial sleep mechanism) effect on seizures in patients with intractable epilepsy. This pilot study might justify a larger study to confirm these findings in order to include melatonin in the armamentarium for intractable epilepsy.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was performed at the Epilepsy Clinic of Schneider Children’s Medical Center of Israel. All authors have participated in the work and take public responsibility for appropriate portions of the content.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073811435916"><label>Author Contributions</label>
<p>HG-S was responsible for substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; and final approval of the version to be published. HO was responsible for substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data. NP was responsible for revising it critically for important intellectual content. B-ZG was responsible for drafting the article or revising it critically for important intellectual content; and final approval of the version to be published.</p></fn>
<fn fn-type="conflict" id="fn2-0883073811435916"><label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073811435916"><label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article. </p>
</fn>
<fn fn-type="other" id="fn4-0883073811435916"><label>Ethical Approval</label>
<p>The study protocol was approved by the Helsinki Committee of Rabin Medical Center, Petach Tikva, Israel. All participating patients or their legal guardians (for those younger than 18 years) signed an informed consent form.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073811435916">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brzezinski</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Melatonin in humans</article-title>. <source>New Engl J Med</source>. <year>1997</year>;<volume>336</volume>:<fpage>186</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr2-0883073811435916">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dodge</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Melatonin for treatment of sleep disorders in children with developmental disabilities</article-title>. <source>J Child Neurol</source>. <year>2001</year>;<volume>16</volume>:<fpage>581</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr3-0883073811435916">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Whitehouse</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Melatonin treatment for sleep disorders in children with neurodevelopmental disorders: an observational study</article-title>. <source>Dev Med Child Neurol</source>. <year>2002</year>;<volume>44</volume>:<fpage>339</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr4-0883073811435916">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peled</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Shorer</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Peled</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pillar</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Melatonin effect on seizures in children with severe neurologic deficit disorders</article-title>. <source>Epilepsia</source>. <year>2001</year>;<volume>42</volume>:<fpage>1208</fpage>–<lpage>1210</lpage>.</citation>
</ref>
<ref id="bibr5-0883073811435916">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smits</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nagtegaal</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Van der Heijden</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial</article-title>. <source>J Child Neurol</source>. <year>2001</year>;<volume>16</volume>:<fpage>86</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr6-0883073811435916">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pillar</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shahar</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Peled</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Melatonin improves sleep-wake patterns in psychomotor retarded children</article-title>. <source>Pediatr Neurol</source>. <year>2000</year>;<volume>23</volume>:<fpage>225</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr7-0883073811435916">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jan</surname>
<given-names>JE</given-names>
</name>
</person-group>. <article-title>The treatment of sleep disorders with melatonin</article-title>. <source>Dev Med Child Neurol</source>. <year>1994</year>;<volume>36</volume>:<fpage>97</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr8-0883073811435916">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palm</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Blennow</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wetterberg</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Long-term melatonin treatment in blind children and young adults with circadian sleep- wake disturbances</article-title>. <source>Dev Med Child Neurol</source> <year>1997</year>;<volume>39</volume>:<fpage>319</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr9-0883073811435916">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braam</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Smits</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Didden</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis</article-title>. <source>Dev Med Child Neurol</source>. <year>2009</year>;<volume>51</volume>:<fpage>340</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr10-0883073811435916">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anton-Tay</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Melatonin: effects on brain function</article-title>. <source>Adv Biochem Psychopharmacol</source>. <year>1974</year>;<volume>11</volume>:<fpage>315</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr11-0883073811435916">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scalise</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Desiato</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Gigli</surname>
<given-names>GL</given-names>
</name>
<etal/>
</person-group> <article-title>Increasing cortical excitability: a possible explanation for the proconvulsant role of sleep deprivation</article-title>. <source>Sleep</source>. <year>2006</year>;<volume>29</volume>:<fpage>1595</fpage>–<lpage>1598</lpage>.</citation>
</ref>
<ref id="bibr12-0883073811435916">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fariello</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Bubenik</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Grown</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Grota</surname>
<given-names>LJ</given-names>
</name>
</person-group>. <article-title>Epileptogenic action of intraventricularly injected antimelatonin antibody</article-title>. <source>Neurology</source>. <year>1977</year>;<volume>27</volume>:<fpage>567</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr13-0883073811435916">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golombek</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Fernández Duque</surname>
<given-names>D</given-names>
</name>
<name>
<surname>De Brito Sánchez</surname>
<given-names>MG</given-names>
</name>
<etal/>
</person-group> <article-title>Time-dependent anticonvulsant activity of melatonin in hamsters</article-title>. <source>Eur J Pharmacol</source>. <year>1992</year>;<volume>210</volume>:<fpage>253</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr14-0883073811435916">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niles</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Pickering</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Arciszewski</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Effect of chronic melatonin administration of GABA and diazepam binding in rat brain</article-title>. <source>J Neural Transm</source>. <year>1987</year>;<volume>70</volume>:<fpage>117</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr15-0883073811435916">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castroviejo</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Rosenstein</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Romeo</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Cardinali</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Changes in gamma-aminobutyric acid high affinity binding to cerebral cortex membranes after pinealectomy or melatonin administration to rats</article-title>. <source>Neuroendocrinology</source>. <year>1986</year>;<volume>43</volume>:<fpage>24</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr16-0883073811435916">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muñoz-Hoyos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sánchez-Forte</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Molina-Carballo</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group> <article-title>Melatonin’s role as an anticonvulsant and neuronal protector: experimental and clinical evidence</article-title>. <source>J Child Neurol</source>. <year>1998</year>;<volume>13</volume>:<fpage>501</fpage>–<lpage>509</lpage>.</citation>
</ref>
<ref id="bibr17-0883073811435916">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borowicz</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Kamiński</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gasior</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice</article-title>. <source>Eur Neuropsychopharmacol</source>. <year>1999</year>;<volume>9</volume>:<fpage>185</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr18-0883073811435916">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Aneja</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kohli</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Add-on melatonin improves behavior in children with epilepsy: randomized, double-blind, placebo-controlled trial</article-title>. <source>J Child Neurol</source>. <year>2005</year>;<volume>20</volume>:<fpage>112</fpage>–<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr19-0883073811435916">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Epilepsia</source>. <year>2004</year>;<volume>45</volume>:<fpage>1636</fpage>–<lpage>1639</lpage>.</citation>
</ref>
<ref id="bibr20-0883073811435916">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gupta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>YK</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes</article-title>. <source>Br J Clin Pharmacol</source>. <year>2004</year>;<volume>58</volume>:<fpage>542</fpage>–<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr21-0883073811435916">
<label>21.</label>
<citation citation-type="journal">
<collab collab-type="author">Proposal for revised clinical and electrographic classification of epileptic seizures</collab>. <article-title>From the Commission on Classification and Terminology of the International League Against Epilepsy</article-title>. <source>Epilepsia</source>. <year>1981</year>;<volume>22</volume>:<fpage>489</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr22-0883073811435916">
<label>22.</label>
<citation citation-type="journal">
<collab collab-type="author">Proposal for revised classification of epilepsies and epileptic syndromes</collab>. <article-title>Commission on Classification and Terminology of the International League Against Epilepsy</article-title>. <source>Epilepsia</source>. <year>1989</year>;<volume>30</volume>:<fpage>389</fpage>–<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr23-0883073811435916">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ross</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Whitehouse</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Melatonin treatment of sleep-wake cycle disorders in children and adolescents</article-title>. <source>Dev Med Child Neurol</source>. <year>1999</year>;<volume>41</volume>:<fpage>850</fpage>.</citation>
</ref>
<ref id="bibr24-0883073811435916">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molina-Carballo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Muñoz-Hoyos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reiter</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group> <article-title>Utility of high dose of melatonin as adjunctive therapy in a child with severe myoclonic epilepsy: two years’ experience</article-title>. <source>J Pineal Res</source>. <year>1997</year>;<volume>23</volume>:<fpage>97</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr25-0883073811435916">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paprocka</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dec</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jamroz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Marszal</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Melatonin and childhood refractory epilepsy—a pilot study</article-title>. <source>Med Sci Monit</source>. <year>2010</year>;<volume>16</volume>: <fpage>CR389</fpage>–<lpage>CR396</lpage>.</citation>
</ref>
<ref id="bibr26-0883073811435916">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bazil</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Short</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crispin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Patients with intractable epilepsy have low melatonin, which increases following seizures</article-title>. <source>Neurology</source>. <year>2000</year>;<volume>56</volume>:<fpage>1746</fpage>–<lpage>1748</lpage>.</citation>
</ref>
<ref id="bibr27-0883073811435916">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandi-Perumal</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Spence</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group> <article-title>Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source>. <year>2006</year>;<volume>31</volume>:<fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr28-0883073811435916">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheldon</surname>
<given-names>SH</given-names>
</name>
</person-group>. <article-title>Pro-convulsant effects of oral melatonin in disabled children</article-title>. <source>Lancet</source>. <year>1998</year>;<volume>351</volume>:<fpage>1254</fpage>.</citation>
</ref>
<ref id="bibr29-0883073811435916">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Iervolino</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mastrosimone</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial</article-title>. <source>Brain Dev</source>. <year>2004</year>;<volume>26</volume>:<fpage>373</fpage>–<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr30-0883073811435916">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Geijlswijk</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>van der Heijden</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Egberts</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group> <article-title>Dose finding of melatonin for chronic idiopathic childhood sleep onset insomnia</article-title>. <source>Psychopharmacology</source>. <year>2010</year>;<volume>212</volume>(<issue>3</issue>):<fpage>379</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr31-0883073811435916">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braam</surname>
<given-names>W</given-names>
</name>
<name>
<surname>van Geijlswijk</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Keijzer</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Loss of response to melatonin treatment is associated with slow melatonin metabolism</article-title>. <source>J Intellect Disab Res</source>. <year>2010</year>;<volume>54</volume>:<fpage>547</fpage>–<lpage>555</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>